ArticleDiabetology & metabolic syndrome2026
Insulin-resistance indices and cardiovascular mortality in cardiovascular-kidney-metabolic syndrome stage 2: a comparative analysis of eGDR, TyG and METS-IR.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Comparative associations of the TyG index and METS-IR with arterial stiffness in women: a cross-sectional analysis by menopausal status.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCardiovascular–kidney–metabolic syndrome stage 2 (CKM–S2) markedly elevates cardiovascular mortality. Insulin-resistance (IR) surrogates—including the triglyceride-glucose (TyG) index, metabolic score for insulin resistance (METS-IR) and estimated glucose-disposal rate (eGDR)—may improve risk stratification, yet their comparative performance in CKM–S2 is unknown.
methodsWe analysed 13,098 adults with CKM–S2 from NHANES 2001–2018. TyG, METS-IR and eGDR were calculated at baseline. Cardiovascular mortality through 31 December 2019 was ascertained via National Death Index linkage. Associations were tested with survey-weighted Cox models, Kaplan–Meier curves and restricted cubic splines; predictive gain over a clinical base model was quantified with C-statistics, net re-classification improvement (NRI), integrated discrimination improvement (IDI) and likelihood ratio (LR) test.
resultsDuring a median follow-up of 103 months, 732 cardiovascular deaths occurred. eGDR showed a linear, inverse relation with cardiovascular mortality (adjusted HR per unit = 0.91, 95% CI 0.87–0.95). TyG and METS-IR exhibited U-shaped curves: risk rose sharply above TyG = 8.78 and METS-IR ≈ 46.8. Adding eGDR to the base model improved the C-statistic from 0.736 to 0.752, NRI by 0.241 and IDI by 0.0176 (all P < 0.001), outperforming TyG and METS-IR.
conclusionseGDR is a robust, linear predictor of cardiovascular death in CKM–S2, whereas TyG and METS-IR convey threshold-dependent risk. Incorporating eGDR routinely and applying cut-off-guided interpretation for TyG and METS-IR could refine clinical risk assessment in CKM–S2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.